Opendata, web and dolomites

COLOSSUS SIGNED

Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "COLOSSUS" data sheet

The following table provides information about the project.

Coordinator
ROYAL COLLEGE OF SURGEONS IN IRELAND 

Organization address
address: Saint Stephen's Green 123
city: DUBLIN
postcode: 2
website: www.rcsi.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website https://www.colossusproject.eu/
 Total cost 5˙996˙359 €
 EC max contribution 5˙996˙359 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ROYAL COLLEGE OF SURGEONS IN IRELAND IE (DUBLIN) coordinator 1˙255˙454.00
2    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 836˙305.00
3    VIB VZW BE (ZWIJNAARDE - GENT) participant 668˙549.00
4    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 468˙676.00
5    HALIODX FR (MARSEILLE) participant 417˙668.00
6    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN IE (DUBLIN) participant 388˙591.00
7    OPTIMATA LTD IL (TEL AVIV) participant 329˙268.00
8    THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL UK (LONDON) participant 300˙146.00
9    GENEXPLAIN GMBH DE (WOLFENBUTTEL) participant 284˙468.00
10    IRISH CLINICAL ONCOLOGY RESEARCH GROUP LIMITED LBG IE (DUBLIN 11) participant 248˙413.00
11    PINTAIL LTD IE (Blackrock) participant 233˙468.00
12    EPIGENOMICS AG DE (BERLIN) participant 230˙518.00
13    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 178˙268.00
14    RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG DE (HEIDELBERG) participant 156˙560.00

Map

 Project objective

Colorectal cancer (CRC) is the third most common cancer in Europe with c. 420,000 cases and 150,000 related deaths in 2012. Of total CRC cases, it is estimated that approximately 50-55 % harbour RAS mutations. Current treatment for RAS mutant (mt) metastatic(m) CRC is primarily based on 5-fluoruracil based chemotherapy /- bevacizumab. However, there are currently limited treatment options once cancers have become resistant. Moreover, while therapy optimization strategies in RAS wild-type CRC patients are feasible, targeted treatment of microsatellite stable (MSS) RAS mt disease is difficult and has not evolved significantly in recent years. COLOSSUS will deliver novel concepts for disease-mechanism based patient stratification in MSS RAS mt mCRC to address the need for stratified or personalised therapeutic interventions in this setting. The consortium will integrate multidimensional and longitudinal omics data to identify new MSS RAS mt specific subtypes with unique signalling dependences. We will harness the power of systems biomedicine, network analysis and computational modelling to identify new actionable pathways, biomarkers and targets across subtypes. These targets will be interrogated in state of the art pre-clinical patient derived xenograft studies. Newly described MSS RAS mt classifiers will be validated as novel patient stratification tools within the COLOSSUS trial. SME partners will develop clinically relevant and commercially viable assays for outcome prediction and stratification of MSS RAS mt patients based on novel classifiers. The impact of assays on CRC associated healthcare costs will further be assessed. Patient associations will be included and the proposal will consider regulatory aspects and commercialisation opportunities, in particular for participating SMEs. mCRC is a complex disease having high prevalence and high economic impact both within a European and global context.

 Deliverables

List of deliverables.
Website/online assets (maintained and updated during project) Websites, patent fillings, videos etc. 2020-01-14 15:07:32

Take a look to the deliverables list in detail:  detailed list of COLOSSUS deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Elke Burgermeister, Francesca Battaglin, Fagr Eladly, Wen Wu, Frank Herweck, Nadine Schulte, Johannes Betge, Nicolai Härtel, Jakob N. Kather, Cleo-Aron Weis, Timo Gaiser, Alexander Marx, Christel Weiss, Ralf Hofheinz, Ian S. Miller, Fotios Loupakis, Heinz-Josef Lenz, Annette T. Byrne, Matthias P. Ebert
Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A
published pages: 139-154, ISSN: 2352-3964, DOI: 10.1016/j.ebiom.2019.07.004
EBioMedicine 45 2019-10-01
2019 Irene Catalano, Livio Trusolino
The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy
published pages: 1-3, ISSN: 1535-6108, DOI: 10.1016/j.ccell.2019.06.001
Cancer Cell 36/1 2019-10-01
2018 Florent Petitprez, Cheng-Ming Sun, Laetitia Lacroix, Catherine Sautès-Fridman, Aurélien de Reyniès, Wolf H. Fridman
Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine
published pages: , ISSN: 2234-943X, DOI: 10.3389/fonc.2018.00390
Frontiers in Oncology 8 2019-10-01
2019 Alice C. O\'Farrell, Ian S. Miller, Rhys Evans, Marina Alamanou, Maurice Cary, Girish Mallya Udupi, Adam Lafferty, Naser Monsefi, Mattia Cremona, Jochen H. M. Prehn, Henk M. Verheul, William M. Gallagher, Mathias Gehrmann, Annette T. Byrne
Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate
published pages: 1800159, ISSN: 1862-8346, DOI: 10.1002/prca.201800159
PROTEOMICS – Clinical Applications 2019-10-01
2018 M. Sturrock, I. S. Miller, G. Kang, N. Hannis Arba’ie, A. C. O’Farrell, A. Barat, G. Marston, P. L. Coletta, A. T. Byrne, J. H. Prehn
Anti-angiogenic drug scheduling optimisation with application to colorectal cancer
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-29318-5
Scientific Reports 8/1 2019-10-01

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COLOSSUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COLOSSUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

DC-ren (2020)

Drug combinations for rewriting trajectories of renal pathologies in type II diabetes (DC-ren)

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More  

SoNAR-Global (2019)

A Global Social Sciences Network for Infectious Threats and Antimicrobial Resistance

Read More